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he transcription factor nuclear factor-
 
 
 
B (NF-
 
 
 
B)
regulates expression of a variety of genes involved
in immune responses, inﬂammation, proliferation,
and programmed cell death (apoptosis). Here, we show
that in rat neonatal ventricular cardiomyocytes, activation
of NF-
 
 
 
B is involved in the hypertrophic response induced
by myotrophin, a hypertrophic activator identiﬁed from
spontaneously hypertensive rat heart and cardiomyopathic
 
human hearts. Myotrophin treatment stimulated NF-
 
 
 
B
nuclear translocation and transcriptional activity, accompa-
nied by I
 
 
 
B-
 
 
 
 phosphorylation and degradation. Consistently,
myotrophin-induced NF-
 
 
 
B activation was enhanced by
T
 
wild-type I
 
 
 
B kinase (IKK) 
 
 
 
 and abolished by the dominant-
negative IKK
 
 
 
 or a general PKC inhibitor, calphostin C.
Importantly, myotrophin-induced expression of two hyper-
trophic genes (atrial natriuretic factor [ANF] and 
 
c-myc
 
)
and also enhanced protein synthesis were partially inhibited
by a potent NF-
 
 
 
B inhibitor, pyrrolidine dithio-carbamate
(PDTC), and calphostin C. Expression of the dominant-
negative form of I
 
 
 
B-
 
 
 
 or IKK
 
 
 
 also partially inhibited the
transcriptional activity of ANF induced by myotrophin.
These ﬁndings suggest that the PKC–IKK–NF-
 
 
 
B pathway
may play a critical role in mediating the myotrophin-induced
hypertrophic response in cardiomyocytes.
 
Introduction
 
Cardiac hypertrophy is a major risk for heart failure and sudden
death (Levy et al., 1990). It has been shown that in animals or
cultured neonatal rat cardiomyocytes, cardiac hypertrophy
can be induced by a combination of mechanical forces and
neurohumoral stimuli, leading to an increase in cardiac protein
synthesis and cell growth through various signaling pathways
(Morgan and Baker, 1991; Glennon et al., 1995; Kijima et al.,
1996; Dostal et al., 1997; Hefti et al., 1997).
In cultured neonatal rat cardiomyocytes, both mechanical
and biochemical stimuli cause changes in gene expression
that closely parallel the hypertrophied heart in vivo. This
includes the sequential activation of different proto-oncogenes
and hypertrophic marker genes such as atrial natriuretic factor
(ANF)* and 
 
 
 
-myosin heavy chain (Izumo et al., 1987,
1988; Iwaki et al., 1990; Chien et al., 1991; Gammage and
Franklyn, 1991; Sadoshima et al., 1992; Takahashi et al.,
1992; Sadoshima and Izumo, 1993; Liang et al., 1997). The
signaling mechanism of the hypertrophic response remains
incompletely understood. Significant efforts have been directed
toward the identification of factor(s) involved in the hyper-
trophic process. Myotrophin, a 12-kD soluble protein, was
originally identified by Sen et al. (1990) from spontaneously
hypertrophied rat hearts and cardiomyopathic human hearts
(Sen et al., 1990; Sil et al., 1993). It has been shown that
myotrophin can initiate hypertrophy, with increased contractile
protein synthesis, induction of proto-oncogenes and hyper-
trophic marker genes, and activation of PKC associated with
an increase in surface area of the myocyte and the appearance of
organized myofibrils within 48 h (Mukherjee et al., 1993;
Sil et al., 1993, 1995, 1998). In addition, myotrophin expres-
sion is elevated under different hypertrophic conditions
(Mukherjee et al., 1993). The gene coding for myotrophin
has been cloned (Sivasubramanian et al., 1996) and structural/
functional motif analysis revealed that it contains ankyrin
repeats and putative phosphorylation sites for PKC and casein
kinase II. Recently, we reported that myotrophin can bind to
 
 
 
B DNA sequence, and by using various parameters, both in
vitro and in vivo systems, we have shown that myotrophin–
 
 
 
B
DNA interaction is an important step in the initiation process
of cardiac hypertrophy (Gupta and Sen, 2002).
 
Nuclear factor-
 
 
 
B (NF-
 
 
 
B) was first identified as a B cell
nuclear factor and was given its name on the basis of its abil-
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ity to bind to an enhancer of the immunoglobulin 
 
 
 
 light
chain gene (Sen and Baltimore, 1986). Since then, NF-
 
 
 
B
has been identified as a ubiquitous inducible transcription
factor that activates a number of genes (Baeuerle and Balti-
more, 1996; Baldwin, 1996; May and Ghosh, 1998). The
I
 
 
 
B kinase (IKK) complex is a multiprotein complex with a
molecular weight of 700–900 kD (Zandi et al., 1997). The
IKK complex contains two catalytic subunits, IKK
 
 
 
 and
IKK
 
 
 
 (also known as IKK-1 and IKK-2, respectively) (Zandi
et al., 1997), and an essential regulatory subunit, NEMO/
IKK
 
 
 
/IKKAP1 (Brockman et al., 1995; Zandi et al., 1997;
Rothwarf et al., 1998; Yamaoka et al., 1998). IKK is acti-
vated by protein phosphorylation induced by a variety of
stimuli, from proinflammatory cytokines to physical stress
(Chen et al., 1996; DiDonato et al., 1997; Regnier et al.,
1997; Woronicz et al., 1997; Zandi et al., 1997, 1998;
Zandi and Karin, 1999). Once activated, IKK phosphory-
lates I
 
 
 
Bs, a group of cytoplasmic NF-
 
 
 
B inhibitors, on spe-
cific serine residues (Ser32 and Ser36 in I
 
 
 
B
 
 
 
, and Ser19
and Ser23 in I
 
 
 
B
 
 
 
), triggering their ubiquitination and sub-
sequent degradation by the 26S proteasome (Traenckner et
al., 1994; Thanos and Maniatis, 1995; Whiteside, 1995).
Degradation of I
 
 
 
B unmasks NF-
 
 
 
B’s nuclear translocation
signal, which allows NF-
 
 
 
B to translocate into the nucleus,
where it stimulates transcription of specific target genes that
are involved in immune responses, inflammation, viral infec-
Figure 1. Stimulation of NF- B activity 
by myotrophin in primary neonatal rat 
cardiomyocytes. (A) Neonatal myocytes 
were grown on coverslips, serum starved 
for 24 h, and treated with myotrophin 
(b) or left untreated (a). Cells were 
treated with calphostin C and PDTC 
before myotrophin treatment (c and d). 
Cells were also pretreated with TNF  (f) 
or left untreated (e) and used as a control. 
Cells were fixed, blocked, and stained 
with p65 mAb followed by anti–mouse 
Texas red (Molecular probe). The nuclear 
translocation of NF- B p65 subunit was 
visualized by confocal microscopy. 
(B) Primary neonatal myocytes were 
transfected with 2X NF- B reporter 
plasmid (1  g/ well) and treated with 
myotrophin for 24 h or left untreated. 
Also, cells were transfected with empty 
vector and treated with PDTC, calphostin 
C, and chelerythrine chloride before 
myotrophin treatment. Cells were 
harvested and the Luc activity was 
determined and normalized to the protein 
content of each extract. Luc activity 
expressed by cells transfected with empty 
vector was given an arbitrary value
of 1. The results are presented as the 
mean   SEM and represent three
individual experiments. P   0.01
compared with the control (untreated). 
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tion, and cell survival (Brown et al., 1995; Chen et al., 1995;
Finco and Baldwin, 1995; Li et al., 1999). NF-
 
 
 
B has been
shown to play a pivotal role in the induction of gene expres-
sion during ischemic adaptation and heart failure (Huarte
and Stutz, 1992; Das et al., 1995; Maulik et al., 1998;
Ritchie, 1998; Chen et al., 1999; Xuan et al., 1999; De Mar-
tin et al., 2000; Li et al., 2001). The potential role of hyper-
trophic agonist–mediated NF-
 
 
 
B activation in neonatal
myocytes has also been reported (Peng et al., 1995; Brasier et
al., 2000; Rouet-Benzineb et al., 2000). Recently, it has been
shown that in cultured neonatal cardiomyocytes, activation
of NF-
 
 
 
B by various hypertrophic agonists (Purcell et al.,
2001b) is necessary for the hypertrophic response. Because
myotrophin can activate PKC in neonatal cardiomyocytes
(Sil et al., 1998) and PKC is involved in NF-
 
 
 
B activation
(Goodfriend et al., 1996), we explored NF-
 
 
 
B activation in
response to myotrophin in neonatal cardiomyocytes and its
involvement in hypertrophic gene expression.
 
Results
 
Stimulation of NF-
 
 
 
B activity by myotrophin in 
neonatal cardiac myocytes
 
To evaluate the role of NF-
 
 
 
B in regulating hypertrophic
growth in cardiomyocytes, we tested whether myotrophin
can stimulate NF-
 
 
 
B. Neonatal myocytes were grown on
laminin-coated coverslips, serum starved, and treated with
myotrophin. Myotrophin stimulated the nuclear transloca-
tion of p65 (Red), a member of the NF-
 
 
 
B family, as mea-
sured by indirect immunofluorescence assays (Fig. 1 A, b).
Pyrrolidine dithio-carbamate (PDTC), an inhibitor of NF-
 
 
 
B, and calphostin C, a PKC inhibitor, blocked myotro-
phin-induced NF-
 
 
 
B translocation (Fig. 1 A, c and d). The
nuclear translocation of p65 was detected 30 min after treat-
ment with myotrophin, with kinetics similar to TNF-
 
 
 
–
treated cells (Fig. 1 A, e and f).
To determine whether myotrophin could stimulate NF-
 
 
 
B transcriptional activity, neonatal myocytes were grown
in six-well plates, transiently transfected with the 2X NF-
 
 
 
B–luciferase (Luc) reporter gene, serum starved, and
treated with myotrophin. Myotrophin significantly stimu-
lated NF-
 
 
 
B transcriptional activity 3.1-fold (Fig. 1 B), as
measured by activation of the NF-
 
 
 
B–Luc reporter gene.
Cells pretreated with calphostin C, chelerythrine chloride,
and PDTC for 1 h before treatment with myotrophin had a
partial inhibition in NF-
 
 
 
B transcriptional activity of 1.16-,
1.34-, and 1.22-fold, respectively (Fig. 1 B). Thus, NF-
 
 
 
B
appears to be a novel target of myotrophin in neonatal myo-
cytes and its activation appears to be PKC dependent.
 
Myotrophin induces NF-
 
 
 
B binding activity 
in neonatal myocytes and is PKC dependent
 
To investigate whether myotrophin could stimulate NF-
 
 
 
B
binding activity in neonatal myocytes, an electrophoretic
mobility shift analysis (EMSA) was performed. Nuclear ex-
tracts of myotrophin-treated cells were prepared and 
 
32
 
P-
labeled NF-
 
 
 
B DNA was used as a probe. Myotrophin treat-
ment stimulated NF-
 
 
 
B binding activity as shown in Fig. 2
A. The specific binding of NF-
 
 
 
B in the myotrophin-treated
neonatal myocytes was confirmed by the addition of 100-
fold molar excess of unlabeled NF-
 
 
 
B competitor DNA into
the EMSA reaction. Fig. 2 A shows that the unlabeled NF-
 
 
 
B DNA competed for binding in nuclear extracts prepared
from myotrophin-treated neonatal myocytes. The presence
of NF-
 
 
 
B in the protein complex was demonstrated by anti-
body supershift assays. The antibody (p65) considerably
shifted the major myotrophin-induced NF-
 
 
 
B binding com-
plex (Fig. 2 A) and PDTC inhibited this binding activity
(unpublished data). To define the possible role of PKC in
this activation process, neonatal myocytes were treated with
calphostin C before treatment with myotrophin. Formation
of the NF-
 
 
 
B complex was partially inhibited in the presence
of calphostin C, as shown in Fig. 2 B. Further characteriza-
tion of NF-
 
 
 
B activation was performed by Western blot us-
Figure 2. Myotrophin stimulates NF- B DNA binding activity. 
(A) Neonatal myocytes were cultured for 3 d and treated with or 
without myotrophin for 1 h. Nuclear proteins were isolated and 
binding reactions were performed with an NF- B oligonucleotide 
labeled with [
32P]dATP. The complex identified could be specifically 
eliminated with excess unlabeled NF- B oligonucleotide. The 
complex formation was also confirmed by supershift analysis using 
p65 antibody. This figure is representative of five different experiments. 
(B) Cells were cultured for 1 h in the presence or absence of 
calphostin C and then treated with myotrophin for 1 h. The remainder 
of the procedure was performed as described in A. (C) Western 
blotting analysis of translocation of NF- B p65 protein into the 
nucleus. Cells were treated with myotrophin for 30 and 60 min. In 
another set, cells were treated with calphostin C and PDTC before 
the treatment with myotrophin. Cytoplasmic and nuclear fractions 
were made and Western blots were performed using a p65 mAb. 
The bottom panel shows the Western blot using histones as a 
standard for nuclear proteins. 
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ing a p65-specific monoclonal antibody. Cardiomyocytes
were pretreated with calphostin C and PDTC before myo-
trophin. Fig. 2 C shows the Western blot profile of cytoplas-
mic and nuclear fractions from these cells. Our data indicate
that myotrophin induces NF-
 
 
 
B translocation to the nucleus
within 30 min of treatment, whereas calphostin C and
PDTC prevent the translocation, suggesting that PKC is in-
volved in the translocation process. To verify that no con-
tamination of nuclear protein in the cytoplasmic fraction had
occurred, we performed Western blots with an antihistone
monoclonal antibody. Our data showed that there was no
histone protein in the cytoplasmic fraction, suggesting that
the fraction was devoid of nuclear protein.
 
Activation of NF-
 
 
 
B by myotrophin in 
neonatal myocytes depends on phosphorylation 
and degradation of I
 
 
 
B-
 
 
 
 proteins and activation 
of the IKK complex
 
A key regulatory step in NF-
 
 
 
B activation is stimulation-
induced, ubiquitination-dependent degradation of I
 
 
 
B
 
 
 
proteins by the 26S proteasome (Traenckner et al., 1994;
Thanos and Maniatis, 1995; Whiteside, 1995), a process
catalyzed by the IKK complex (Brockman et al., 1995; Tha-
nos and Maniatis, 1995; DiDonato et al., 1997; Regnier et
al., 1997; Woronicz et al., 1997; Rothwarf et al., 1998;
Yamaoka et al., 1998). However, NF-
 
 
 
B can also be acti-
vated independently of stimulation-induced degradation of
I
 
 
 
B-
 
  proteins and IKK activation (Imbert et al., 1996; Li
and Karin, 1998; Frost et al., 2000b; Purcell et al., 2001b).
To determine the molecular mechanism of NF- B activa-
tion by myotrophin, neonatal myocytes were treated with
myotrophin at various time points (10 min to 2 h) and
I B-  phosphorylation and degradation were analyzed. Treat-
ment with myotrophin induced phosphorylation of I B- 
at 15 min that peaked at 60 min and then began to decrease
(Fig. 3 A). Corresponding to the phosphorylation of I B- 
proteins, degradation (Fig. 3 B) began 15 min after treat-
ment with myotrophin, peaked at 60 min, and then recov-
ered at 120 min due to newly synthesized I B- , which is
one of the target genes of NF- B (Brown et al., 1995; Chen
et al., 1995; Finco and Baldwin, 1995; Baldwin, 1996; May
and Ghosh, 1997; Li et al., 1999). In both cases, the level of
actin protein was unchanged (Fig. 3, A and B, bottom). Lac-
tacystin, an inhibitor of the threonine protease of the protea-
some, inhibited myotrophin-induced I B-  phosphoryla-
tion and degradation (Fig. 3, A and B). These results suggest
that myotrophin-induced degradation of I B-  proteins is a
phosphorylation-dependent process. Furthermore, lactacys-
tin prevented the nuclear translocation of NF- B in the
myotrophin-treated neonatal myocytes, as evidenced by EMSA
(unpublished data). To determine whether PKC was in-
volved in this process, myocytes were treated with calphostin
C and both the phosphorylation and degradation statuses of
I B-  were measured. We observed that myotrophin-
induced I B-  phosphorylation and degradation were com-
pletely inhibited in the presence of calphostin C, suggesting
that PKC may indeed play a role in this process (Fig. 3, A
and B). To further determine the molecular mechanism of
NF- B activation during this initiation process of hypertro-
phy, neonatal myocytes were cotransfected with the 2X NF-
 B–Luc gene with or without the expression vector encod-
ing the I B-  (32Ala/36Ala) mutant, which is resistant to
stimulation-induced degradation and functions as a suppres-
sor of NF- B activation. Cells were treated with myotrophin
for 24 h or left untreated. Expression of the I B-  mutant
completely blocked the stimulation of NF- B–Luc activity
by myotrophin (Fig. 3 C). These data, together, suggest that
stimulation-dependent I B-  degradation is required for
myotrophin-induced NF- B activation.
The IKK complex mediates activation of NF- B by vari-
ous extracellular stimuli, such as TNF-  and IL-1 (Karin,
1999; Israel, 2000). To determine whether the myotrophin-
induced activation of NF- B in cardiomyocyte hypertrophy
is mediated by IKK , neonatal cardiomyocytes were tran-
siently transfected with the 2X NF- B–Luc reporter gene,
with or without expression vectors encoding HA–IKK  (Fig.
Figure 3. NF- B activation by myotrophin 
involves phosphorylation and degradation of I B . 
(A) Neonatal myocytes were serum starved and 
incubated in the absence (control) or presence of 
myotrophin for various time periods. Cells were 
harvested and cell extracts (50  g) were analyzed 
for phosphorylation of I B  using a kit from Cell 
Signaling Technology. Endogenous actin (bottom) 
was analyzed as a control. (B) Intracellular levels 
of I B  were also determined in the absence 
(control) or presence of myotrophin using the same 
kit as stated above. Endogenous protein levels 
were determined using an actin antibody (bottom). 
(C) Neonatal cardiomyocytes were transiently 
transfected with 2X NF- B–Luc (1  g/well), with or 
without the repressor I B  (32Ala/36Ala) mutant 
(200 ng/well). Cells were serum starved and then 
treated with myotrophin for 24 h or left untreated. 
Cells were then harvested and Luc activity was 
determined as described in Fig. 1 B. The results are 
presented as the mean   SEM and represent three 
individual experiments. P   0.05 compared with 
the control (untreated).NF- B activation in myotrophin-induced cardiac hypertrophy | Gupta et al. 1023
4 C), HA–IKK  (177Ala/181Ala) mutant (Fig. 4 D), or ve-
hicle. Cells were treated with myotrophin for 24 h or left un-
treated. Fig. 4 C shows the approximately fourfold activation
of the NF- B–Luc reporter gene (lane 2) in myotrophin-
treated cells. Expression of wild-type IKK  potentiated the
stimulation of the NF- B–Luc reporter activity by myotro-
phin, leading to a 10.8-fold activation (Fig. 4 C, lane 4). Po-
tentiation of the NF- B–Luc reporter activity by IKK  and
myotrophin was synergistic because IKK  alone only in-
duced a 3.8-fold activation (Fig. 4 C). We examined whether
the HA–IKK  (177Ala/181Ala) mutant, which has been
previously shown to function as a dominant-negative mutant
to block NF- B activation by several stimuli (Nemoto et al.,
1998a), was able to block myotrophin-induced NF- B tran-
scriptional activity. Expression of the dominant-negative
IKK  (177Ala/181Ala) mutant significantly inhibited the
NF- B–Luc activity by myotrophin (Fig. 4 D). PDTC and
calphostin C blocked myotrophin-induced NF- B transcrip-
tional activity (unpublished data). Taken together, these data
suggest that myotrophin-induced activation of NF- B is me-
diated by the IKK  complex and PKC is involved.
If the IKK complex mediates the activation of NF- B by
myotrophin in neonatal cardiomyocytes, myotrophin should
stimulate IKK activity. Fig. 4 A shows that myotrophin can
stimulate IKK  activity. After 15 min of myotrophin treat-
ment, IKK  activity was stimulated 3.7-fold (Fig. 4 A). The
enhanced activity persisted for up to 30 min and then de-
creased. Primary cardiomyocytes were also transfected with
HA–IKK , followed by treatment with myotrophin at vari-
ous times (15–60 min). We observed that HA–IKK  was
transiently activated 15 min after treatment with myotro-
phin (a 2.9-fold increase) followed by a gradual decrease
(Fig. 4 B). This activation was not a result of increased HA–
IKK  expression, as confirmed by immunoblotting (Fig. 4
B, bottom). The data suggest that myotrophin-induced NF-
 B activation is mediated by IKK .
Myotrophin enhances I B-  mRNA expression
Because myotrophin can stimulate NF- B, we investigated
the activation of one of its downstream target genes, I B- .
To determine the level of I B-  mRNA expression in myo-
trophin-treated neonatal myocytes, we performed Northern
blot analysis using cDNA for I B-  and GAPDH as an in-
ternal control. Myocytes were treated with myotrophin at
various time points (15, 30, 45, and 60 min) and RNA was
prepared. The results are shown in Fig. 5. Myotrophin stim-
ulated the expression of I B-  mRNA in a time-dependent
manner. I B-  mRNA levels increased 3.05- and 3.3-fold
after 15 and 30 min of myotrophin treatment, respectively,
and peaked (3.9-fold) at 45 min compared with that of con-
Figure 4. Activation of NF- B by myotrophin is 
mediated through the IKK complex. (A) Neonatal 
myocytes were treated with or without (control) 
myotrophin for various times. Cells were harvested, 
cell extracts (500  g) were immunoprecipitated with 
IKK  antibody, and kinase activity was determined 
by using GST–I B  as a substrate (Li et al., 2001). 
(B) Neonatal cardiomyocytes were transfected with 
HA–IKK  (1  g/well) or empty vector. After 36 h, 
cells were treated with myotrophin (40 nmol) for 
various times or left untreated, as indicated. HA–
IKK  was immunoprecipitated and immunocomplex 
kinase assays were performed using GST–I B  as a 
substrate as previously described (Li et al., 2001). 
Substrate phosphorylation was quantitated and the 
fold induction is given in the bottom panel. An 
aliquot of each lysate was analyzed for HA–IKK  
content by immunoblotting using HA antibody. 
(C) Neonatal cardiomyocytes were cotransfected 
with 2X NF- B–Luc reporter plasmid (1  g/ well) and 
expression vector HA–IKK  (200 ng/ well) or (D) the 
dominant-negative HA–IKK  (177Ala/181Ala) 
(50 ng/well) or empty vector, as indicated. Cells were 
treated with myotrophin for 24 h or left untreated. 
Cells were washed, harvested, and Luc activity was 
determined as described in the legend for Fig. 1 B. 
The results are presented as the mean   SEM and 
represent three individual experiments.
Figure 5. Myotrophin induces expression of I B  mRNA. Neonatal 
myocytes were incubated in the absence (control) or presence of 
myotrophin at various times. RNA was extracted as described in the 
Material and methods. I B  mRNA expression was determined using a 
cDNA probe for I B  labeled with [
32P]dCTP. Results are presented 
in three individual experiments. A GAPDH oligo was used as a probe 
for an internal loading control. Fold stimulation is indicated (lower).1024 The Journal of Cell Biology | Volume 159, Number 6, 2002
trol myocytes (no stimulation). PDTC and calphostin C
partially inhibited the expression of I B-  mRNA (1.65-
and 1.8-fold, respectively), suggesting a PKC/NF- B–depen-
dent pathway for myotrophin-induced I B-  synthesis.
Attenuating NF- B inhibits myotrophin-induced 
protein synthesis and hypertrophic gene expression 
in myocytes
The experimental results above suggest that NF- B may be
important for myotrophin-stimulated hypertrophy. To test
this scenario, we determined the effect of inhibition of NF-
 B on myotrophin-induced protein synthesis and cardiac
gene expression (i.e., ANF and c-myc). The effect of block-
ing NF- B by PDTC on myotrophin-induced total protein
synthesis in myocytes was analyzed by measuring [
3H]leu-
cine incorporation. Total protein synthesis was increased
( 78%) in cells exposed to myotrophin (40 nmol) for 24 h
compared with controls (n   3) (Fig. 6 A). Myotrophin-
induced protein synthesis was inhibited ( 18.6%) by PDTC
and also by myotrophin antibody (Myo-Ab) by 6.8% over
the control (Fig. 6 A). Myotrophin significantly stimulated
PKC activity in neonatal myocytes, and this activity was in-
hibited by calphostin C (unpublished data). To evaluate the
involvement of PKC in myotrophin-induced protein syn-
thesis, calphostin C or chelerythrine chloride were added to
the [
3H]leucine incorporation assay. We found that calphos-
tin C and chelerythrine chloride inhibited myotrophin-induced
[
3H]leucine incorporation by 16.8% and 18.68%, respec-
tively, over the controls (Fig. 6 A). These results demonstrate
that myotrophin-stimulated protein expression may depend
on NF- B and PKC activity.
An important feature of cardiac hypertrophy is the reex-
pression of ANF and induction of immediate early genes
such as c-myc (Lattion et al., 1986; Starksen et al., 1986;
Izumo et al., 1988; Mercadier et al., 1989; Gammage
and Franklyn, 1991). To determine whether myotrophin-
induced expression of different hypertrophic genes, such as
ANF and c-myc, depends on NF- B, we incubated myo-
cytes with or without PDTC and performed Northern blot
analysis. The results are shown in Fig. 6 B. Our data indi-
cated that myotrophin-induced ANF and c-myc gene expres-
sion was partially inhibited by PDTC. This suggests that
NF- B may participate in the expression of this hyper-
trophic marker gene. To determine whether activation of
these genes is mediated by PKC, we incubated myocytes
with or without calphostin C in the presence of myotrophin.
Calphostin C caused inhibition of ANF and c-myc expres-
sion (Fig. 6 B). Taken together, this suggests that myotro-
phin-induced hypertrophic gene expression may be PKC
and NF- B dependent.
NF- B activation may be necessary for the 
expression of myotrophin-induced ANF 
in the initiation of cardiac hypertrophy
To evaluate whether NF- B is necessary for the transcrip-
tion of cardiac hypertrophy marker genes in neonatal myo-
cytes, we measured the effect of NF- B inhibition on myo-
trophin-induced expression of ANF. Myotrophin induced
ANF–Luc activity 6.1-fold (Fig. 7 A) and expression of the
HA–I B  (32 Ala/36 Ala) mutant, which inhibits NF- B,
attenuated the myotrophin-induced ANF–Luc activity (Fig.
7 A). Additionally, myotrophin-induced activation of the
ANF–Luc reporter gene was potentiated by expression of
wild-type IKK  (10.8-fold) (Fig. 7 B), and the HA–IKK 
(177Ala/181Ala) mutant, which is resistant to NF- B, at-
tenuated myotrophin-induced ANF–Luc activity (Fig. 7 B).
Discussion
It has been reported that activation of NF- B occurs in
congestive heart failure and with unstable angina pectoris
(Ritchie, 1998; Wong et al., 1998). However, NF- B acti-
vation in the myotrophin-induced initiation processes of
cardiac hypertrophy has not been studied. Our study sug-
gests that NF- B activation is necessary for myotrophin-
induced hypertrophic gene expression and is PKC depen-
dent. This conclusion is based on several lines of evidence.
First, myotrophin stimulated the nuclear translocation of
Figure 6. Effect of PDTC, calphostin C, and 
chelerythrine chloride on myotrophin-induced 
protein synthesis and gene expression in neonatal 
rat cardiomyocytes. (A) Neonatal myocytes were 
pretreated with myotrophin antibody (Myo-Ab), 
100  M PDTC, 1  M of calphostin C, and 10  M 
chelerythrine chloride for 60 min and then treated 
with myotrophin for 24 h in the presence of 
[
3 H]leucine. Cells were lysed and incorporation of 
[
3H]leucine into myocytes was measured as 
described in the text. Data shows the means 
( SEM) of three different sets of results. P values 
compared with control or unstimulated cells. 
(B) Samples from control and myotrophin-treated 
neonatal myocytes were treated with or without 
100  M PDTC and 1  M of calphostin C. Total 
RNA (20  g) was hybridized separately with 
[
32P]dATP-labeled c-myc, ANF, or GAPDH 
oligo probes.NF- B activation in myotrophin-induced cardiac hypertrophy | Gupta et al. 1025
NF- B and its transcriptional activity in primary cardio-
myocytes (Fig. 1, A and B). Also, myotrophin induced
NF- B DNA binding activity (Fig. 2 A). Second, myotro-
phin induced phosphorylation and degradation of endoge-
nous I B  (Fig. 3, A and B). Lactacystin, a specific protea-
some inhibitor, blocked phosphorylation and degradation
of I B-  by myotrophin (Fig. 3, A and B). Activation of
NF- B by myotrophin appeared to depend on I B  degra-
dation because it was inhibited by expression of the super-
repressor I B  (32Ala/36Ala) mutant (Fig. 3 C). Further-
more, NF- B activation by myotrophin was potentiated by
expression of wild-type IKK  (Fig. 4 C) but inhibited by
the dominant-negative IKK  (177Ala/181Ala) mutant
(Fig. 4 D). Myotrophin consistently stimulated both en-
dogenous IKK  and HA–IKK  activity (Fig. 4, A and B),
as well as mRNA expression of an NF- B target gene,
I B  (Fig. 5). Third, myotrophin increased protein syn-
thesis, as quantified by enhanced [
3H]leucine incorporation
into myocyte protein, which was inhibited by both PKC
and NF- B inhibitors (Fig. 6 A). Additionally, we have
shown previously that treatment of myocytes with myotro-
phin resulted in a dose-dependent increase in cell size
(quantified by measuring cell surface area) associated with
organization of myofibrils, compared with untreated con-
trol myocytes (Sen et al., 1990). Myotrophin treatment
also enhanced gene expression of ANF and c-myc (Fig.
6 B). Fourth, myotrophin-induced gene transcription of
ANF was inhibited by expression of the I B  (32Ala/
36Ala) mutant (Fig. 7 A), or the dominant-negative IKK 
(177Ala/181Ala) mutant (Fig. 7 B), but was potentiated by
wild-type IKK  (Fig. 7 B). Finally, calphostin C, a PKC
inhibitor, attenuated myotrophin-induced NF- B activa-
tion and expression of ANF and c-myc (Figs. 1–3, 5, and
7). This finding suggests that PKC is involved in myotro-
phin-dependent activation of NF- B during the initiation
of cardiac hypertrophy in neonatal myocytes.
The kinetics of NF- B translocation, I B-  degradation,
and IKK  activity by hypertrophic agonists such as PE,
ET-1, or AngII (Brasier et al., 2000; Rouet-Benzineb et al.,
2000; Purcell et al., 2001b) are very similar to those induced
by myotrophin presented in this study. In this report, we
have shown that myotrophin acts as a potent hypertrophic
stimulus that activates NF- B through the degradation and
phosphorylation of I B  in cardiomyocytes to initiate hy-
pertrophy. It is not clear how exogenously added myotro-
phin exerts its action in cultured neonatal myocytes to pro-
duce cardiomyocyte hypertrophy. One possibility is that
myotrophin has a receptor-mediated mode of action, as evi-
denced by our previous results (Sil et al., 1998) and those of
Anderson et al. (1999), where preliminary studies suggest
the presence of a specific myotrophin binding protein in the
cardiac membrane. Future work is needed to reveal the de-
tails of the mechanism of myotrophin action.
Recently, Knuefermann et al. (2002) reported that myo-
trophin can interact with NF- B (p50 and P65) proteins.
The authors have postulated that myotrophin promotes the
formation of p50–p50 homodimers from monomeric p50
protein, can convert preformed p50–p65 heterodimers into
p50–p50 and p65–p65 homodimers, and appears to play an
important role in modulating the level of activated NF- B
dimers during hypertrophy or heart failure process.
Therefore, data from the present study suggest that myo-
trophin acts on IKK  (Fig. 4, A–D) and then dissociates the
NF- B complex (Figs. 2 and 3), thereby allowing NF- B to
enter the nucleus and activate hypertrophy marker genes
(Fig. 6 B). The whole cascade is PKC dependent.
Hypertrophic growth of cardiac myocytes is a complex
phenomenon (Thorburn et al., 1994a). Many cellular sig-
naling pathways, e.g., mitogen-activated protein kinases
(ERK, JNK, and p38) (Thorburn et al., 1994a,b; Gillespie-
Brown et al., 1995; Nemoto et al., 1998b), gp130 (Frost et
al., 2000a), and various growth factors (Hefti et al., 1997;
Molkentin et al., 1998; Sussman et al., 1998; Olson and
Molkentin, 1999), have been reported to be involved in
cardiomyocyte hypertrophy. Such in vitro approaches have
dissected out some of the pathways involved in the intracel-
lular signal transduction cascade and subsequent activation
of a set of genes involved in hypertrophy. Therefore, a lat-
eral crosstalk may occur upon stimulation by a factor(s)
that may act alone, or in concert in a synergistic manner
(Hefti et al., 1997). Recent studies have shown that the ac-
tivation of p38 or the ERK pathway may also contribute to
NF- B activation (Lindroos et al., 1998; Carter et al.,
1999; Craig et al., 2000; Vanden Berghe et al., 2000).
Therefore, the hypertrophic process is likely an outcome of
a combination of many signaling pathways (Chien, 1999,
2000; Vanden Berghe et al., 2000). Further studies are
needed to explore the crosstalk between NF- B and other
signaling pathways to elucidate the mechanisms that ini-
tiate cardiac hypertrophy.
Figure 7. Inhibition of NF- B blocks myotrophin-
induced ANF gene expression in neonatal rat 
cardiomyocytes. (A) Neonatal myocytes were 
transfected with ANF–Luc reporter plasmid 
(1  g/ well) with or without HA–I B  (32Ala/36Ala) 
mutant (200 ng/well), (B) wild-type HA–IKK  
(200 ng/well), or the dominant-negative HA–IKK  
(177Ala/181Ala) (50 ng/well). Cells were washed 
and harvested. Luc activity was determined as 
described in Fig. 1 B. The results are presented as 
the mean   SEM and represent three individual 
experiments. P   0.05 compared with the control.1026 The Journal of Cell Biology | Volume 159, Number 6, 2002
Materials and methods
Materials
Timed pregnant rats were obtained from Hilltop Farms. The rats were fed
Purina rat chow, given water as needed, and housed in AAALAC-certified
facilities. Sprague-Dawley rats weighing 250–300 g (Harlan Sprague Daw-
ley, Inc.) were used for preparation of neonatal myocytes. All experimental
procedures used with our animals were in accordance with National Insti-
tutes of Health guidelines. The p65 antibody, GST–I B , and double-
stranded NF- B DNA (5 -AGT TGA GGG GAC TTT CCC AGG C-3 ) were
purchased from Santa Cruz Biotechnology, Inc. IKK  antibody was pur-
chased from Upstate Biotechnology. T4 polynucleotide kinase, [
32P]dATP,
[
32P]dCTP, [
3H]leucine, protein A–agarose, and NAP-5 column were pur-
chased from Amersham Biosciences. I B  degradation and phosphoryla-
tion were measured using a kit from Cell Signaling Technology. ANF, c-myc,
and GAPDH oligonucleotides were purchased from Oncogene Research
Products. DME F-12, nonessential amino acids, antibiotics, Tris-borate
EDTA, and PBS were purchased from Life Technologies. All other media
and reagents used for preparation and culture of the neonatal myocytes, in-
cluding medium, BSA, insulin, transferrin, fetuin, hydrocortisone, and lami-
nin, were purchased from Sigma-Aldrich. Collagenase was purchased from
Worthington Biochemicals. Heparin and pentobarbital were purchased
from Elkins-Sinn, Inc. and Abbott Laboratories, respectively. Calphostin C,
chelerythrine chloride, lactacystin, PDTC, and protease inhibitor cocktail
were purchased from CalBiochem. Alexa
®488-conjugated goat anti–rabbit
IgG and Alexa
®594-conjugated goat anti–mouse IgG were purchased from
Molecular Probes, Inc. Vectashield with DAPI was purchased from Vector
Laboratories. All other chemicals used in this study were of molecular biol-
ogy grade and were purchased from Sigma-Aldrich.
Preparation of neonatal cardiac myocytes
Neonatal myocytes were prepared according to the procedure described
by Sen et al. (1990). In brief, hearts from 2–3-d-old normal Wistar Kyoto
rat pups were aseptically taken in DME, and the ventricles were separated,
minced, and incubated in DME containing collagenase (80 U/ml). Myo-
cytes were plated on laminin-coated wells (20  g/35-mm well) at a density
of 10
6 cells/35-mm well. On culture day 3 (or 4), myocytes were incubated
in DME alone and were used for the experiment as required. BrdU, at 0.1
mmol/liter, was used throughout the experimental procedure to inhibit the
growth of cardiac fibroblast. Myocytes were confirmed by staining with
 -actinin ( 80–90% myocytes).
Cell treatment
To study the effect of myotrophin on NF- B activation, neonatal myocytes
were treated with 40 nmol of myotrophin at various times. For inhibitor
studies, cells were pretreated with desired inhibitors at specific times. Cells
were then washed with cold PBS, harvested, and total cell lysates were
prepared. The doses of calphostin C and PDTC were selected after pilot
experiments using different doses of the respective inhibitors. A dose of 1
 M for calphostin C, 10  M chelerythrine chloride, and 100  M PDTC
showed the optimal inhibition without damaging the myocytes.
Measurement of protein synthesis
To determine the total protein synthesis in myotrophin-induced myocyte
growth, we performed a bioassay according to Sen et al. (1990). In brief,
on culture day 3, neonatal myocytes were preincubated in serum-free
DME that contained 1  M calphostin C, 10  M chelerythrine chloride, or
100  M PDTC for 60 min. Then 40 nmol myotrophin was added and the
incubation continued for 16–24 h at 37 C. [
3H]leucine (10  Ci) diluted in
DME was added to each well and incubated for 2 h at 37 C. The protein
from each individual well was filtered using a cell harvester, collected on
individual filter paper discs, and washed extensively with 5% TCA until
they were free from radioactivity. The filter papers were air dried and
counted in a   scintillation counter after addition of 5 ml scintillation fluid.
Data were expressed as disintegration per minute. At least three indepen-
dent sets of experiments were performed.
Preparation of recombinant myotrophin
Recombinant myotrophin was expressed and purified as described previ-
ously (Sivasubramanian et al., 1996).
cDNA constructs and transfection
The following constructs were used in this study and have been described
previously (Purcell et al., 2001a): expression vectors encoding HA-tagged
IKK , dominant-negative HA–IKK  (177 Ala/181 Ala) mutant, in which
serines 177 and 181 were replaced by nonphosphorylatable alanine (Ala),
and HA–I B  (32 Ala/36 Ala) mutant, in which serines 32 and 36 were re-
placed by Ala. Reporter genes for ANF–Luc and NF- B–Luc were de-
scribed previously by Purcell et al., 2001b. In brief, reporter genes for
ANF–Luc, in which the full-length rat promoter ( 3003) was fused to the
firefly Luc gene, and 2X NF- B–Luc, in which two copies of the  B pro-
moter containing the NF- B binding site was fused to the Luc gene.
Transfections and Luc assay
Primary neonatal cardiomyocytes were transiently transfected with the 2X
NF- B–Luc or ANF–Luc reporter genes with or without various expression
vectors encoding HA–IKK , the dominant-negative mutant HA–IKK 
(177Ala/181 Ala), and the dominant-negative HA–I B-  (32Ala/36Ala) mu-
tant by using Tfx-20 (Promega) according to the manufacturer’s instructions.
After transfection, cells were washed four times in plain medium (DME F-12)
and maintained in serum-free medium with or without myotrophin, as indi-
cated in the figure legends. Luc activity and normalization of the protein
content of each extract were determined by using the dual luciferase re-
porter assay system (Promega) according to the manufacturer’s protocol.
Immunocytochemistry and confocal microscopy
Cell fixation and permeabilization were performed according to the proto-
col of Rouet-Benzineb et al. (2000). The primary antibody was p65 mAb
and the secondary antibody was Alexa
®568 goat anti–mouse IgG (H L)
conjugate at a 1:1,000 dilution. Immunofluorescent NF- B p65 staining
was observed using a laser scanning confocal microscope. Confocal im-
ages were collected using a Leica TCS-SP spectral laser scanning confocal
microscope that was equipped with two argon ion lasers (364 and 488 nm)
and a krypton/argon ion laser (568 nm). A PlanApo 20 , 0.7 oil immer-
sion objective lens was used. To compare the staining patterns, digitized
images for Texas red and DAPI red channels were acquired from the same
area and merged to determine overlap in the staining pattern raised from
the antibody to NF- B p65 and the intercalating agent DAPI.
Cytoplasmic and nuclear protein extracts
After the appropriate experimental treatment, cultures of neonatal myo-
cytes were rinsed with cold PBS. Nuclear and cytoplasmic extracts were
made according to the methods described previously by Dignam et al.
(1983). All buffers were kept on ice unless stated otherwise. PMSF, DTT,
and protease inhibitor cocktail were added just before use. The cytoplas-
mic and nuclear extracts were normalized for protein amounts determined
by Bradford assay using BSA as a standard (Bio-Rad Laboratories protein
assay kit). Protein fractions were aliquoted and stored at  70 C.
Western blot analysis
Cytoplasmic and nuclear protein extracts from cardiomyocytes were made
as described above. NF- B protein was assayed by Western blot in cyto-
plasmic or nuclear extracts from neonatal myocytes using primary anti-
body against p65 according to the method described by Rouet-Benzineb et
al. (2000). The immunoreactive complex was visualized using chemilumi-
nescence according to manufacturer’s protocol (NEN). Phosphorylation
and degradation of I B  protein was assayed in extracts of neonatal myo-
cytes by Western blotting using a kit from Cell Signaling Technology. Ex-
tracts (50  g) from each sample were separated by 10% SDS-PAGE. The
assays were performed according to the manufacturer’s protocol.
Kinase activity assay
Approximately 500  g of cytoplasmic proteins from each sample was im-
munoprecipitated with IKK  antibody and protein A–agarose at 4 C for
1 h. The kinase assay was performed using GST–I B  as a substrate ac-
cording to the protocol by Li et al. (2001).
EMSA
An EMSA was performed using a double-stranded NF- B binding site oli-
gonucleotide as a probe. The double-stranded NF- B DNA was labeled
with [
32P]dATP using T4 polynucleotide kinase and purified using a NAP-5
column. 10  g of nuclear protein was incubated in a final volume of 20  l
binding buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM DTT, 40 mM
NaCl, 5% glycerol, 1  g/ml poly [dI:dC]) on ice for 10 min. The oligonu-
cleotide (50,000 cpm) was added, and the reaction mixture was incubated
for an additional 20 min at room temperature. For the supershift assay,
specific antibody was added just after ice incubation, and the mixture was
incubated for another 10 min at room temperature. For the competition
studies, specific competitor (100-fold molar excess) was added along with
the binding buffer. After incubation, DNA–protein complexes were sepa-NF- B activation in myotrophin-induced cardiac hypertrophy | Gupta et al. 1027
rated from the unbound DNA probe on a native 4% polyacrylamide gel in
low ionic strength buffer (0.25  TBE) by electrophoresis at 100 V for 3 h
with circulation of the buffer. After electrophoresis, the gel was dried and
exposed to Kodak X-AR films at  70 C.
RNA isolation and Northern blot analysis of I B , ANF, and c-myc
Total RNA was isolated from rat neonatal myocytes using the QIAGEN RNA
isolation kit. The concentration of total RNA isolated was quantified by UV
spectrophotometry at 260/280 nm. For Northern blot hybridization, 20  g
of total RNA was denatured at 70 C for 20 min and fractionated by electro-
phoresis on 1% agarose gel containing 1  MOPS buffer (20 mM MOPS, 5
mM sodium acetate, and 10 mM EDTA). Northern blotting and hybridiza-
tion using ANF, c-myc, and GAPDH probes were performed as described
previously (Mukherjee et al., 1993). For I B  probe preparation, an I B 
cDNA (provided by Allan Braiser, University of Texas Medical Branch,
Galveston, TX) was made using a random primer labeling system (Promega).
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